Abstract
We have evaluated the effects of an anti-CD2 monoclonal antibody (moAb), Leu-5b, on inhibition of lymphocyte responsiveness. Given previous reports that anti-CD2 moAb prevent production of interleukin 2 (IL 2), as well as up-regulation of IL 2 receptor, we chose a test system in which lymphocytes were activated by exogenously added recombinant IL 2 (rIL 2). Our studies thus allowed us to evaluate other possible mechanisms by which anti-CD2 moAb could act. We found that Leu-5b not only blocked the proliferative response of human peripheral blood leukocytes (PBL) to IL 2, but also the development of cytotoxicity as assayed in lectin-dependent cytotoxicity (LDCC). Addition of recombinant interleukin 1β (rIL 1β) reconstituted the proliferative response in the presence of Leu-5b but did not allow development of cytotoxicity. Our findings are consistent with the concept that Leu-5b delivers a signal to IL 2-responsive cells that prevents their subsequent proliferation and development of cytotoxicity, but that only the former event, i.e., proliferation, is reconstituted by the addition of IL 1β.
| Original language | English |
|---|---|
| Pages (from-to) | 2155-2160 |
| Number of pages | 6 |
| Journal | Journal of Immunology |
| Volume | 138 |
| Issue number | 7 |
| State | Published - May 27 1987 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Role of CD2 and IL 1β in T cell responsiveness to IL 2. / Gromo, G.; Geller, R. L.; Inverardi, Luca A; Wee, S. L.; Bach, F. H.
In: Journal of Immunology, Vol. 138, No. 7, 27.05.1987, p. 2155-2160.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of CD2 and IL 1β in T cell responsiveness to IL 2
AU - Gromo, G.
AU - Geller, R. L.
AU - Inverardi, Luca A
AU - Wee, S. L.
AU - Bach, F. H.
PY - 1987/5/27
Y1 - 1987/5/27
N2 - We have evaluated the effects of an anti-CD2 monoclonal antibody (moAb), Leu-5b, on inhibition of lymphocyte responsiveness. Given previous reports that anti-CD2 moAb prevent production of interleukin 2 (IL 2), as well as up-regulation of IL 2 receptor, we chose a test system in which lymphocytes were activated by exogenously added recombinant IL 2 (rIL 2). Our studies thus allowed us to evaluate other possible mechanisms by which anti-CD2 moAb could act. We found that Leu-5b not only blocked the proliferative response of human peripheral blood leukocytes (PBL) to IL 2, but also the development of cytotoxicity as assayed in lectin-dependent cytotoxicity (LDCC). Addition of recombinant interleukin 1β (rIL 1β) reconstituted the proliferative response in the presence of Leu-5b but did not allow development of cytotoxicity. Our findings are consistent with the concept that Leu-5b delivers a signal to IL 2-responsive cells that prevents their subsequent proliferation and development of cytotoxicity, but that only the former event, i.e., proliferation, is reconstituted by the addition of IL 1β.
AB - We have evaluated the effects of an anti-CD2 monoclonal antibody (moAb), Leu-5b, on inhibition of lymphocyte responsiveness. Given previous reports that anti-CD2 moAb prevent production of interleukin 2 (IL 2), as well as up-regulation of IL 2 receptor, we chose a test system in which lymphocytes were activated by exogenously added recombinant IL 2 (rIL 2). Our studies thus allowed us to evaluate other possible mechanisms by which anti-CD2 moAb could act. We found that Leu-5b not only blocked the proliferative response of human peripheral blood leukocytes (PBL) to IL 2, but also the development of cytotoxicity as assayed in lectin-dependent cytotoxicity (LDCC). Addition of recombinant interleukin 1β (rIL 1β) reconstituted the proliferative response in the presence of Leu-5b but did not allow development of cytotoxicity. Our findings are consistent with the concept that Leu-5b delivers a signal to IL 2-responsive cells that prevents their subsequent proliferation and development of cytotoxicity, but that only the former event, i.e., proliferation, is reconstituted by the addition of IL 1β.
UR - http://www.scopus.com/inward/record.url?scp=0023110944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023110944&partnerID=8YFLogxK
M3 - Article
C2 - 3104452
AN - SCOPUS:0023110944
VL - 138
SP - 2155
EP - 2160
JO - Journal of Immunology
JF - Journal of Immunology
SN - 0022-1767
IS - 7
ER -